hat
Ester la Hexahydrobenzylcarbonate devlope mwatye lavi tranbolon a nan limit a apeprè 14 jou olye ke 3 jou, ki se mwatye lavi a nan Trenbolone Acetate. Trenbolon nan toude fòma te wè anpil peryòd de itilize kòm yon dwòg apwouve medikal pou itilizasyon imen, kòm tranbolon Acetate te commercialisés pou yon tan kout pandan ane 1980 yo kòm Finajet ak Finaject anvan yo te rale soti nan mache a ak disapproved pou itilize imen anviron 1987. Parabolan te jije plis apwopriye pou itilize imen pandan kouri li yo sou mache a dwòg preskripsyon akòz aji pi long li yo ak pi dousman divilge pase tranbolon Acetate,
eng
The Hexahydrobenzylcarbonate ester extends Trenbolone’s half-life to the extent of approximately 14 days rather than 3 days, which is the half-life of Trenbolone Acetate. Trenbolone in both formats saw very brief periods of use as an approved medical drug for human use, as Trenbolone Acetate was marketed for a brief time during the 1980s as Finajet and Finaject before being pulled from the market and disapproved for human use circa 1987. Parabolan was deemed more suitable for human use during its run on the prescription drug market due to its longer acting and slower releasing properties than Trenbolone Acetate,